Eledon Pharmaceuticals (NASDAQ:ELDN) used a presentation at the Leerink Partners Global Healthcare Conference to highlight ...

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to tegoprubart for the prevention of ...

IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to ...

US FDA grants orphan drug designation to Eledon Pharma’s tegoprubart for prevention of allograft rejection in liver transplantation: Irvine, California Thursday, March 12, 2026, ...

Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation ...

IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon”) (NASDAQ: ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug ...

The alloimmune response against fully MHC-mismatched allografts, compared with immune responses to nominal antigens, entails an unusually large clonal size of alloreactive T cells 1. Thus, induction ...

You will be redirected to our submission process. Allograft fibrosis represents a key contributor to chronic graft dysfunction and late transplant failure. It arises from continuous tissue injury and ...

Keywords allograft rejection, biopsies, kidney transplantation, metabolomics, urine test Citation Wiesner K, Schiffer E, Putz FJ, Robertson A, Mark S, Reichelt-Wurm S, Schmidt KM, Santamaría AS, Banas ...